Calcium gluconate

Generic Medicine Info
Patients with hypercalcaemia or conditions associated with hypercalcaemia (e.g. hyperparathyroidism, hypervitaminosis D, neoplastic disease with bone decalcification, immobilisation osteoporosis), hypercalciuria, severe renal failure. IV: Concomitant use with ceftriaxone in premature (up to corrected age of 41 weeks [weeks of gestation and life]) or full-term neonates (≤28 days of age).
Special Precautions
Patients with cardiac impairment, nephrocalcinosis, sarcoidosis (Boeck's disease), severe hypokalaemia, hypomagnesemia, Ca renal calculi or history of renal calculi, calculi formation in the urinary tract, severe hyperphosphatemia. Renal impairment. Children. Pregnancy and lactation. Patients receiving cardiac glycosides. Monitoring Parameters Monitor serum Ca concentrations (every 4-6 hours during intermittent infusions or every 1-4 hours during continuous infusion); albumin, serum phosphate, and Mg; ECG and vitals (as necessary).
Adverse Reactions
Significant: Bradycardia with vasodilatation or arrhythmia. Gastrointestinal disorders: Gastrointestinal irritation, nausea, vomiting, chalky taste. General disorders and administration site conditions: Soft tissue calcification, heat sensations, sweating, local tissue inflammation, local necrosis, calcinosis cutis. Musculoskeletal and connective tissue disorders: Tingling sensation. Nervous system disorders: Anxiety. Vascular disorders: Hypotension, flushing (rapid inj), syncope.
Potentially Fatal: Circulatory collapse.
Drug Interactions
Increased risk of hypercalcaemia with thiazide diuretics and vitamin D or A. May enhance effects and toxicity of cardiac glycosides (e.g. digoxin). Enhanced β-adrenergic effects of epinephrine. May decrease the absorption and effects of Ca channel blockers (e.g. verapamil), bisphosphonates (e.g. alendronate), oral fluoroquinolones, and tetracyclines.
CIMS Class
Antidotes, Detoxifying Agents & Drugs Used in Substance Dependence / Electrolytes
ATC Classification
A12AA03 - calcium gluconate ; Belongs to the class of calcium-containing preparations. Used as dietary supplements.
D11AX03 - calcium gluconate ; Belongs to the class of other dermatologicals.
Disclaimer: This information is independently developed by CIMS based on calcium gluconate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in